How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/regional-anesthesia-for-ophthalmologic-surgery.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Regional Anesthesia for Ophthalmologic Surgery — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Regional Anesthesia for Ophthalmologic Surgery (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Regional Anesthesia for Ophthalmologic Surgery, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Bupivacaine Hydrochloride And Epinephrine	BUPIVACAINE	Innocoll	Amide Local Anesthetic	Cytochrome P450 2D6	1972-01-01
Bupivacaine Hydrochloride	Bupivacaine Hydrochloride	Pfizer	Amide-type local anesthetic	Nerve sodium channels	1972-01-01
Lignospan Forte	Lidocaine Hydrochloride	Fresenius Kabi	local anesthetic, amide type	neuronal membrane ionic channels	1948-01-01
Lignocaine	Lignocaine	University of Malaya		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Lidocain	Lidocain	Bayer		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
xylocain	xylocain	Saint-Joseph University		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Bupivacain	Bupivacain	Sisli Hamidiye Etfal Training and Research Hospital		5-hydroxytryptamine receptor 3A, Cytochrome P450 2D6, Potassium channel subfamily K member 3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bayer · 1 drug in Regional Anesthesia for Ophthalmologic Surgery
Fresenius Kabi · 1 drug in Regional Anesthesia for Ophthalmologic Surgery
Innocoll · 1 drug in Regional Anesthesia for Ophthalmologic Surgery
Pfizer · 1 drug in Regional Anesthesia for Ophthalmologic Surgery
Saint-Joseph University · 1 drug in Regional Anesthesia for Ophthalmologic Surgery
Sisli Hamidiye Etfal Training and Research Hospital · 1 drug in Regional Anesthesia for Ophthalmologic Surgery
University of Malaya · 1 drug in Regional Anesthesia for Ophthalmologic Surgery

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Regional Anesthesia for Ophthalmologic Surgery:

Cite this brief

Drug Landscape (2026). Regional Anesthesia for Ophthalmologic Surgery — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/regional-anesthesia-for-ophthalmologic-surgery. Accessed 2026-06-11.

Regional Anesthesia for Ophthalmologic Surgery full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing